BioCentury
ARTICLE | Product Development

Accelerating the Accelerator

How J&Js plans to intercept COPD, gestational diabetes, HPV-driven cancer

March 28, 2016 7:00 AM UTC

One year out from the launch of its Disease Interception Accelerator, Janssen Research & Development LLC is rapidly developing new insights into how to study the transition from health to disease. Two of the group's newest disease ventures are starting by mining repositories of longitudinal data and biological samples to study how gestational diabetes and chronic obstructive pulmonary disease begin.

"We will go where the longitudinal data exist, and then revalidate in other populations," said Benjamin Wiegand, global head of the Disease Interception Accelerator (DIA)...